Energy and redox biology
Researchers study oxidative phosphorylation, redox balance, metabolites, organelle quality control, and how energy failure affects different tissues.
Research
Mitochondrial disease research, explained clearly.
Follow therapeutic approaches, disease mechanisms, recent publications, clinical trials, patient registries, and MDA-supported research pathways—then see how patients can participate without skipping trust.
If you already know the disease area, start with the matching program page so MDA can review fit before outreach.
Research landscape
From mitochondrial mechanisms to patient-informed studies.
Mitochondrial DNA maintenance
Replication, repair, nucleotide balance, heteroplasmy, deletion burden, and mtDNA expression are central to many disease programs.
Small molecules and metabolic approaches
Studies investigate compounds intended to alter energy metabolism, stress responses, inflammation, or downstream disease effects. Evidence remains condition-specific.
Genetic and RNA approaches
Nucleases, base editing, gene replacement, RNA delivery, and allotopic expression are active research areas, many still preclinical or early stage.
Natural history and biomarkers
Longitudinal cohorts, patient-reported outcomes, imaging, laboratory markers, and digital measures help make future trials interpretable.
Clinical trials
Interventional and observational studies test safety, efficacy, endpoints, and disease course.
Browse directoryData network breadth
More kinds of participants make the public picture more representative.
MDA can route people across disease programs, suspected diagnoses, caregivers, family advocates, different geographies, and approved comparison volunteers when a program allows it. When more people return with complete updates over time, that broader picture makes cohort readiness easier to judge and gives researchers a clearer view of longitudinal depth, while governed access keeps detailed health records in Mito Map.
Use the smallest useful public ask.
Keep detailed records and private permissions in Mito Map.
Point people to the matching program or data-network page instead of collecting everything up front.
Research library
Recent and foundational reading
Plain-language note: review articles synthesize a field; they do not prove that every discussed approach is safe or effective.
Therapies: past, present, and future
A peer-reviewed overview of dietary, small-molecule, organ-replacement, and genetic approaches.
Read at PubMed CentralMolecular mechanisms and therapeutic applications
A broad review of disease mechanisms, diagnosis, and emerging therapeutic strategies.
Read the reviewClinical trials directory
Source-linked study identifiers, conditions, phases, sponsors, and verification dates.
Browse studiesCondition research clusters
Gene- and syndrome-specific context with links to programs, registries, trials, and community.
Explore conditionsReviewed publications and plain-language summaries live on the Publications page when they are ready; this page stays focused on research questions, fit, and review.
Funded and supported work
Accountable project reporting
MDA will list a project here only when its investigator, institution, funding or support type, dates, aims, conflicts, status, and return-of-results plan can be published. No externally funded MDA project is represented as active unless those fields are verified.
Current status
No externally funded MDA research project is publicly verified in this directory yet. This explicit empty state prevents planning concepts from being mistaken for funded work.
Submission pathway
Researchers can propose a study below. Governance review, participant consent, and a defined return of value are required before work proceeds.
Reporting standard
Future entries will show milestones, aggregate participation, outputs, publications, and material changes without exposing private participant data.
Open opportunities
6Available for member review
Programs with opportunities
6Current active disease paths
Sponsors represented
1Across open requests
Participation choices
One at a timeEach opportunity is reviewed separately
Patient partnership
Better research starts with clear questions and patient trust.
See whether a program may fit
Researchers can review public program activity and ask about aggregate readiness without seeing private records. Consent-aware registry readiness can help shape study design and recruitment planning, but it does not identify individuals or promise enrollment.
Explain the request
Every proposal should say what is being studied, why it matters, what data is needed, and how much time patients may spend.
Give something back
Approved work should return useful summaries, publications, or plain-language findings when appropriate.
Protect patients first
Recruitment and data requests move forward only after review and consent, using the smallest useful amount of information.
For pharma and biotech
Use governed summaries to test the question before you spend on protocol work.
MDA can help sponsor teams check whether a study idea is worth a deeper review by showing aggregate readiness, likely burden, and the right disease program fit. That can reduce avoidable rework, but it does not promise faster enrollment, lower spend, or trial success. If the work turns into sponsored collaboration, proof-packet review, or a contract conversation, MDA routes it to the partner path.
Start with the smallest useful question.
Ask for feasibility, burden, and evidence needs before broader planning.
Use reviewed summaries instead of raw records for early decisions.
Move partner work through the governed review path before any outreach or data use.
Before outreach
Check whether a study idea is worth deeper planning before asking patients for time.
Use aggregate counts and program activity to see whether enough people may fit the question.
Review the likely time burden before asking patients to complete another survey or study task.
Use the smallest useful ask so weak fits can be ruled out before more protocol or recruitment work starts.
Keep early planning focused on group-level signals, not names, records, or direct patient access.
Biomarkers and endpoints
Use the right evidence level for each marker.
Use validated clinical endpoints where they already exist, and label them as established measures only when the source is explicit.
Treat wearable summaries, digital function measures, phenotype clusters, and intervention-response patterns as candidate measures or exploratory signals until they are independently reviewed and better supported.
Ask whether a proposed marker is meant for diagnosis, cohort stratification, natural history, trial planning, or endpoint development so the review path matches the claim.
MDA can surface consent-aware summary data and cohort readiness signals that help teams test feasibility, burden, and fit before protocol work starts, and those same signals can help tell whether a biomarker or endpoint idea is ready for closer review, still exploratory, or too thin to guide protocol work.
Evidence key: validated endpoint means the field already accepts the measure; candidate measure means it is useful but still being reviewed; exploratory signal means it can shape planning, but not a claim of proof.
What to include
A good request is specific and easy to review.
The research question
Say exactly what you want to learn and why mitochondrial disease patients may care.
The patient group
Name the disease area, age group, diagnosis status, or other fit criteria you expect.
The data need
Ask for the smallest useful dataset, and say whether aggregate summaries are enough.
The patient burden
Estimate the time, tasks, visits, surveys, samples, or follow-up patients would face.
The return to families
Explain whether patients will get a summary, publication update, resource, or other useful result.
What you do not need
Do not ask for raw records, names, or broad access if a limited summary can answer the question.
Better models and predictions
Consented longitudinal data can help aggregate models, prediction checks, and cohort readiness stay current.
When people return with updates, the timeline is fresher, so analysis can compare like with like instead of mixing an old snapshot with a newer one.
More complete summaries help aggregate models and review tools spot patterns earlier, compare groups more fairly, and judge whether a cohort is ready for a question or still needs more context before it should be used for planning.
Broader participation across ages, disease patterns, and care settings can reduce blind spots in planning and prediction, but it does not guarantee a correct result for any one person.
If Mito Map surfaces study matches, profile gaps, or follow-up prompts from consented summaries, those are review cues only, not medical advice, a diagnosis, or a treatment plan.
Cohort usefulness
What makes a cohort more useful over time.
| Signal | What it looks like | Why it matters |
|---|---|---|
| More people | More patients and caregivers join the program. | Larger cohorts make it easier to spot real patterns without overreading a small sample. |
| More updates | People return with new symptoms, care changes, or follow-up check-ins in Mito Map. | Repeated updates turn a one-time snapshot into a longitudinal picture. |
| More complete summaries | Key fields are filled in when known, instead of leaving the record thin or partial. | Completeness helps teams judge whether a cohort is ready for review or still needs more context. |
| More consistency | Summaries are verified, consent-aware, and updated under the same rules. | Consistent data is easier to trust for feasibility, recruitment planning, and aggregate reporting. |
MDA uses this level of explanation to encourage participation and return visits. Detailed health records and personalized recommendations stay in Mito Map.
Broader participation
Richer cohorts come from more than one kind of mito story.
Confirmed diagnoses
People with a known mitochondrial diagnosis help anchor program learning with clearer disease-specific context.
Suspected diagnoses
People still working toward a diagnosis can help surface earlier patterns and reduce blind spots before the record is complete.
Caregivers and family advocates
Caregivers can add context, reduce burden, and help keep the story current when the patient wants support.
Different geographies and care settings
Participation from more places and care paths makes the aggregate picture less local and more useful to the community.
Comparison volunteers
Some programs may invite non-mito volunteers so researchers can compare patterns carefully without mixing up different groups.
MDA only asks for the minimum information needed to route a person into the right public path. Detailed health data, records, and consent choices stay in Mito Map or another governed system, depending on the program.
Appropriate uses
Collaboration starts with a clear question.
1. Submit the question
Describe the disease community, data need, expected value, sponsor, and stage of work.
2. Review governance
MDA reviews fit, burden, privacy level, consent requirements, and patient return of value.
3. Move approved work forward
Approved requests move into reviewed systems for consent-aware cohort operations.
Research onboarding
A review-ready proposal is easier to govern and easier to publish later.
Name the disease program, research question, and the specific audience for the result so review can assess fit quickly.
Describe the smallest useful dataset and why aggregate or summary data may be enough before requesting anything broader.
State how you will protect consent, minimize participant burden, and handle withdrawal or data-use restrictions if they arise.
Include how findings will return to the community as a manuscript, abstract, report, milestone update, or plain-language summary when appropriate.
Review workflow
Data access is not approved by a form submission.
Screening
A research reviewer checks the question, disease area, stage, sponsor, and whether MDA is the right front door.
Review
Requests involving participant data, recruitment, or study planning are checked for privacy, consent fit, burden, and conflicts.
Minimum necessary
Approved work is scoped to aggregate, de-identified, limited, or summary data needed for the question.
Returned learning
When appropriate, approved work should return plain-language findings, publications, or useful updates to the community.
Mito Map data categories
Types of information researchers may request
Mito Map can support consented, governed datasets across these categories. Availability is not guaranteed for every participant or program; each request depends on participant-provided data, disease-program scope, consent status, privacy review, de-identification limits, and the minimum necessary dataset for the approved question.
Disease and diagnosis profile
Program enrollment, diagnosis status, symptom or condition tags, mitochondrial disease subtype, age of onset, genetic testing or variant summaries when shared, and relevant family or inheritance context.
Clinical and longitudinal signals
Consented summaries of symptoms, medications, care-team information, labs, imaging or record metadata, hospitalizations, care-use patterns, and changes over time when those fields are captured or imported.
Function and lived experience
Patient-reported outcomes, priority surveys, daily-function measures, fatigue or mobility signals, caregiver observations, and plain-language experience data collected through disease programs.
Connected and summary data
Mito Map state snapshots, wearable daily summaries, digital hand-function or functional testing sessions, questionnaire completion, participation history, consent history, and aggregate program metrics.
Cohort summary reports
Counts by consent, program, symptom burden, function coverage, wearable coverage, lab coverage, longitudinal depth, and survey completion.
Longitudinal change datasets
Baseline and follow-up snapshots across Mito Map state, symptom trajectories, measured function, challenge response, and disease-program check-ins.
Intervention-response signals
Consented summaries of tried interventions, adherence, symptom deltas, energy or function changes, wearable deltas, and confidence scores where available.
Digital function endpoints
Grip, sit-to-stand, fatigue before and after exertion, hand function, dexterity, symmetry, recovery, and functional reserve when collected.
Wearable-derived summaries
Sleep duration and efficiency, heart-rate variability, recovery, resting heart rate, activity load, steps, and next-day symptom or function links where consented.
Phenotype summaries
Symptom clusters, subsystem states, phenotype severity, confidence scores, and analysis-ready features produced under approved methods.
Recruitment support
Consented recontact cohorts, eligibility snapshots, disease-program matching, research waitlist interest, and outreach readiness.
Provenance and return of value
Consent version, data source, collection date, transformation level, de-identification boundary, minimum-necessary review, and plain-language summaries back to participants.
Researchers should expect governed access to aggregate, de-identified, limited, or summary data rather than broad raw-record access. Detailed cohort discovery, recruitment, and approved data requests route through reviewed systems and governance review.
Contact form